Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Chemomab Therapeutics Ltd. - American Depositary Shares (NQ: CMMB ) 2.010 +0.020 (+1.01%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 120,843 Open 2.000 Bid (Size) 1.980 (1) Ask (Size) 2.030 (2) Prev. Close 1.990 Today's Range 1.900 - 2.010 52wk Range 0.4600 - 2.550 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit December 03, 2024 From Chemomab Therapeutics Via GlobeNewswire Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis November 19, 2024 From Chemomab Therapeutics Via GlobeNewswire Performance YTD +273.74% +273.74% 1 Month +12.92% +12.92% 3 Month +30.52% +30.52% 6 Month +120.27% +120.27% 1 Year +279.25% +279.25% More News Read More Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update November 14, 2024 From Chemomab Therapeutics Via GlobeNewswire Earnings Scheduled For November 14, 2024 November 14, 2024 Via Benzinga Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update October 30, 2024 From Chemomab Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session October 15, 2024 Via Benzinga Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024 October 15, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Present at October 2024 Investor Conferences October 01, 2024 From Chemomab Therapeutics Via GlobeNewswire Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 03, 2024 Via Benzinga Chemomab Therapeutics to Present at September 2024 Investor Conferences August 28, 2024 From Chemomab Therapeutics Via GlobeNewswire CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024 August 21, 2024 Via InvestorPlace Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update August 21, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update August 12, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces Closing of $10 Million Private Placement July 30, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement July 26, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise July 25, 2024 Via Benzinga Chemomab Therapeutics Announces $10 Million Private Placement July 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis July 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis June 18, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference June 06, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Participate in Upcoming Scientific Conferences May 17, 2024 From Chemomab Therapeutics Via GlobeNewswire CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024 May 09, 2024 Via InvestorPlace Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule May 08, 2024 From Chemomab Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session May 06, 2024 Via Benzinga Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
